The universal flu vaccine does not need to be reformatted every year and stops people from needing a seasonal flu vaccine.[13] Her first clinical trials, which were in 2008, made use of the Influenza A virus subtype H3N2, and included daily monitoring of the patient's symptoms.[13][14] It was the first study that it was possible to stimulate T cells in response to a flu virus, and that this stimulation would protect people from getting the flu.[13] Her research has demonstrated that the adenoviral vector ChAdOx1 can be used to make vaccinations that are protective against Middle East Respiratory Syndrome (MERS) in mice and able to induce immune response against MERS in humans.[15][16] The same vector was also used to create a vaccine against Nipah which was effective in hamsters (but never proven in humans),[17] in addition to a potential vaccine for Rift Valley Fever that was protective in sheep, goats, and cattle (but not proven in humans).[18]